About hepion pharmaceuticals inc - HEPA
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.
HEPA At a Glance
Hepion Pharmaceuticals, Inc.
55 Madison Avenue, PMB No. 4362
Morristown, New Jersey 07960
| Phone | 1-732-902-4000 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -8,277,850.00 | |
| Sector | Health Technology | Employees | 2 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
HEPA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.717 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.129 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.111 |
HEPA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -4,138,925.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
HEPA Liquidity
| Current Ratio | 10.254 |
| Quick Ratio | 10.254 |
| Cash Ratio | 6.106 |
HEPA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -353.476 |
| Return on Equity | -2,058.632 |
| Return on Total Capital | -304.152 |
| Return on Invested Capital | -2,058.632 |
HEPA Capital Structure
| Total Debt to Total Equity | 2.027 |
| Total Debt to Total Capital | 1.987 |
| Total Debt to Total Assets | 1.761 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |